Quick Answer
Edwards Lifesciences Corp reported Total Revenue of $6.07 billion for the year ending 2025.
- Edwards Lifesciences Corp showed an increase of +11.5% in Total Revenue from 2024 to 2025.
- This data is from Edwards Lifesciences Corp's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2017: $883.50 million | Q2 2017: $841.80 million | Q3 2017: $821.50 million | Q4 2017: $888.50 million | Q1 2018: $894.80 million | Q2 2018: $943.70 million | Q3 2018: $906.60 million | Q4 2018: $977.70 million | Q1 2019: $993.00 million | Q2 2019: $1.09 billion | Q3 2019: $1.09 billion | Q4 2019: $1.17 billion | Q1 2020: $1.13 billion | Q2 2020: $925.00 million | Q3 2020: $1.14 billion | Q4 2020: $1.19 billion | Q1 2021: $1.22 billion | Q2 2021: $1.38 billion | Q3 2021: $1.31 billion | Q1 2022: $1.34 billion | Q2 2022: $1.37 billion | Q3 2022: $1.32 billion | Q1 2023: $1.22 billion | Q2 2023: $1.28 billion | Q3 2023: $1.24 billion | Q4 2023: $1.27 billion | Q1 2024: $1.33 billion | Q2 2024: $1.37 billion | Q3 2024: $1.35 billion | Q4 2024: $1.39 billion | Q1 2025: $1.41 billion | Q2 2025: $1.53 billion | Q3 2025: $1.55 billion.
- Over the full 10 years of available data (2016 to 2025), Edwards Lifesciences Corp's Total Revenue has grown by 104.7%.
- Historical annual values: Fiscal year 2025: $6.07 billion | Fiscal year 2024: $5.44 billion | Fiscal year 2023: $5.01 billion | Fiscal year 2022: $4.46 billion | Fiscal year 2021: $5.23 billion | Fiscal year 2020: $4.39 billion | Fiscal year 2019: $4.35 billion | Fiscal year 2018: $3.72 billion | Fiscal year 2017: $3.44 billion | Fiscal year 2016: $2.96 billion.
- Data sourced from SEC EDGAR public filings as of August 4, 2026.
Last verified: